Adaptive Biotechnologies (ADPT) free cash flow

Free cash flow · fiscal 2025
-$48.95M

Adaptive Biotechnologies (ADPT) generated free cash flow of -$48.95M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$98.88M. Figures as of 18 Nov 2026, 12:27 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2025
-$48.95M
Highest on record
$194.20Mfiscal 2019
Lowest on record
-$254.47Mfiscal 2021
Fiscal years on record
92017–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Adaptive Biotechnologies free cash flow, in more detail

Across the 9 fiscal years on record (2017–2025), the highest was $194.20M in fiscal 2019 and the lowest -$254.47M in fiscal 2021.

History · 9 fiscal years

Free cash flow by fiscal year

Adaptive Biotechnologies free cash flow, year by year

Adaptive Biotechnologies (ADPT) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2025-$48.95M—
2024-$98.88M—
2023-$167.02M—
2022-$200.29M—
2021-$254.47M—
2020-$168.49M 186.8% down
2019$194.20M—
2018-$38.56M—
2017-$37.28M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of Adaptive Biotechnologies and comparable companies
CompanyFree cash flowFiscal year
Dianthus Therapeutics DNTH-$129.27M2025
MiniMed Group MMED-$420.00M2026
Adaptive Biotechnologies ADPT-$48.95M2025
Heartflow HTFL-$59.05M2025
CRISPR Therapeutics CRSP-$370.93M2025
Travere Therapeutics TVTX-$20.37M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on ADPT

Adaptive Biotechnologies, figure by figure

Adaptive Biotechnologies (ADPT) overview: price, valuation and scorecardAll health care companies by market value

Adaptive Biotechnologies free cash flow: questions and answers

What is Adaptive Biotechnologies's free cash flow?

Adaptive Biotechnologies (ADPT) generated free cash flow of -$48.95M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$98.88M.

What are the highest and lowest free cash flow figures on record for Adaptive Biotechnologies?

Across the 9 fiscal years on record (2017–2025), the highest was $194.20M in fiscal 2019 and the lowest -$254.47M in fiscal 2021.

How is Adaptive Biotechnologies's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Adaptive Biotechnologies it is on record here for 9 fiscal years, 2017 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Adaptive Biotechnologies (ADPT) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/ADPT/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.